PDF下载 ( 201 KB)
Analysis of anti-fibrosis effect of combining lamivudine with captopril in 166 cases with chronic hepatitis B
-
摘要: 目的研究联合使用抗病毒药物和血管紧张素转换酶抑制剂治疗慢性乙型肝炎抗肝纤维化疗效。方法回顾性分析单纯降酶治疗、单用拉米夫定、卡托普利、联合拉米夫定和卡托普利治疗一年的166例慢性乙型肝炎患者的临床资料,比较治疗前后肝纤维化血清标志物及肝组织纤维化分期变化情况评价不同治疗方案的抗肝纤维化疗效。结果联合用药组、拉米夫定组、卡托普利组治疗后血肝纤4项水平与治疗前相比有不同程度降低,治疗后肝组织均显示S0～1期比例明显增加,S2～3期、S4期比例显著下降,而降酶组治疗前后肝纤四项水平及肝组织纤维化分期差异无统计学意义。结论使用拉米夫定、卡托普利治疗慢性乙型肝炎均有抗肝纤维化作用,联合使用效果更加明显。Abstract: Objective To study the effect of inhibiting fibrosis of combination treatment with Lamivudine and Captopril on CHB (chronic hepatitis B) .Methods 166 cases with CHB, who were divided into reducing-liver enzyme group, Lamivudine group, Captopril group and combination group with Lamivudine and Captopril according to different therapeutic strategy used on them, were analyzed retrospectively.And the levels of four blood markers and histologic stages on hepatic fibrosis of these cases were evaluated.Results The levels of the four blood markers declined in varying degrees after treatment compared with those before treatment in combination group, Lamivudine group, and Captopril group respectively.At the same time, the rates of histologic stage 0-1 rose remarkably, while the rates of stage 2-3 and stage 4 descended markedly.There were not significant statistic difference between in the levels of the four blood markers and histologic stages in reducing-liver enzyme group before and after treatment.Conclusion Both Lamivudine and Captopril had effect on inhibiting hepatic fibrosis in CHB patients.This effect was more evident when treating CHB with combining Lamivudine with Captopril.
-
Key words:
- chronic hepatitis B /
- liver fibrosis /
- Lamivudine /
- Captopril
-
[1] 中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶324-329. [1] 中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶324-329. [2]Yoshiji H, Kuriyama S, Yoshii J, et al.Angiotensin-Ⅱtype1re-ceptor interaction is a major regulator for liver fibrosis development in rats[J].Hepatology, 2001, 34∶745-750. [2]Yoshiji H, Kuriyama S, Yoshii J, et al.Angiotensin-Ⅱtype1re-ceptor interaction is a major regulator for liver fibrosis development in rats[J].Hepatology, 2001, 34∶745-750. [3]魏红山, 李定国, 陆汉民, 等.血管紧张素Ⅱ受体阻断剂抗肝纤维化的实验研究[J].中华肝脏病杂志, 2000, 8 (5) ∶302-304. [3]魏红山, 李定国, 陆汉民, 等.血管紧张素Ⅱ受体阻断剂抗肝纤维化的实验研究[J].中华肝脏病杂志, 2000, 8 (5) ∶302-304. [4]Jonsson JR, Clouston AD, Ando Y, et al.Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis[J].Gastroenterology, 2001, 121 (1) ∶148-155. [4]Jonsson JR, Clouston AD, Ando Y, et al.Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis[J].Gastroenterology, 2001, 121 (1) ∶148-155. [5]李乾, 张桂英, 李新华, 等.卡托普利抗肝纤维化实验研究[J].中国现代医学杂志, 2003, 13∶22-25. [5]李乾, 张桂英, 李新华, 等.卡托普利抗肝纤维化实验研究[J].中国现代医学杂志, 2003, 13∶22-25. [6]姚光弼.正确认识和评价拉米夫定在治疗慢性乙型肝炎中的地位[J].肝脏, 2002, 7 (2) ∶73. [6]姚光弼.正确认识和评价拉米夫定在治疗慢性乙型肝炎中的地位[J].肝脏, 2002, 7 (2) ∶73. [7]俞平.拉米夫定及联合复方丹参对慢性乙型肝炎肝纤维化指标的影响[J].中华传染病杂志, 2003, 21 (5) ∶346-347. [7]俞平.拉米夫定及联合复方丹参对慢性乙型肝炎肝纤维化指标的影响[J].中华传染病杂志, 2003, 21 (5) ∶346-347. [8]Friedman SL.Mechanisms of hepatic fibrogenesis[J].Gastroenterol-ogy, 2008, 134 (6) ∶1655-1669. [8]Friedman SL.Mechanisms of hepatic fibrogenesis[J].Gastroenterol-ogy, 2008, 134 (6) ∶1655-1669. -
本文二维码
计量
- 文章访问数: 2119
- HTML全文浏览量: 16
- PDF下载量: 731
- 被引次数: 0
下载:
